希夫基和复合物和抗阿尔茨海默氏症的特性
Salih Günnaz1, Esma Yildiz2, Ayça Tunçel Oral3
1Department of Chemistry, Faculty of Science, Ege University, Bornova, Izmir 35100, Turkey.
Journal of inorganic biochemistry
|December 3, 2024
概括
新的和复合物有效抑制了粉样蛋白聚合,这是阿尔茨海默病的关键因素. 这些化合物显示出开发新型阿尔茨海默病治疗方法的前景.
科学领域:
- 无机化学 无机化学
- 神经科学是一个神经科学.
- 材料科学 材料科学 材料科学
背景情况:
- 阿尔茨海默病的特点是粉样β (Aβ) 的聚合.
- 开发有效的Aβ聚合抑制剂对于阿尔茨海默病治疗至关重要.
- 希夫基联体及其金属复合物提供潜在的治疗途径.
研究的目的:
- 合成和表征新的 (Pt) 和 (Ru) 复合物,具有二烯基希夫基结构.
- 评估这些复合物的有效性,以抑制粉样β (Aβ1-42) 聚合在体外.
- 阐明复合物和Aβ之间的相互作用机制.
主要方法:
- 使用FTIR,NMR,质谱学和元素分析合成和表征希夫基联体 (I) 和其Pt (II) (Ia) 和Ru (II) (Ib) 复合物.
- 在体外抑制Aβ1-42聚合,使用SH-SY5Y细胞系,光谱学和传输电子显微镜.
- 通过MALDI-TOF MS和H NMR光谱学研究复杂相互作用,并通过方波电压测量进行电化学分析.
主要成果:
- 合成的Pt和Ru复合体 (Ia和Ib) 已成功准备和表征.
- 这两种复合体都在低摩尔比率下显著抑制了Aβ1-42聚合.
- 光谱和TEM证实了剂量依赖的粉样蛋白聚合抑制.
- 马尔迪-托夫MS,H NMR和电化学方法为相互作用机制提供了洞察力.
结论:
- 新型的Pt (II) 和Ru (II) 希夫基复合体是粉样β聚合的强有力的抑制剂.
- 这些复合物代表了开发新的治疗药物治疗阿尔茨海默病的有希望的候选人.
- 这项研究强调了金属基化合物在神经退行性疾病干预中的潜力.
相关概念视频
Alzheimer's Disease: Treatment
163
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
163
Alzheimer's Disease: Overview
447
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
447
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
96
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
96


